Pro zobrazení tohoto obsahu je třeba být přihlášen.
Author Archives for m.popovic@wemakemedia.cz
COMPARATIVE PERFORMANCE OF PROGNOSTIC SYSTEMS IN PATIENTS WITH MYELOFIBROSIS SECONDARY TO PV AND ET AFTER ALLOGENEIC STEM-CELL TRANSPLANTATION
13 októbra, 2020 5:56 pm Leave your thoughtsAuthor(s): Nico Gagelmann, Diderik-Jan Eikema, Linda Koster, et al. Abstract: S129 Session topic: 16. Myeloproliferative neoplasms – Clinical...
RESURRECTING RESPONSE TO RUXOLITINIB: A PHASE I STUDY TESTING THE COMBINATION OF RUXOLITINIB AND THE PI3K DELTA INHIBITOR UMBRALISIB IN RUXOLITINIB-EXPERIENCED MYELOFIBROSIS
13 októbra, 2020 5:56 pm Leave your thoughtsAuthor(s): Tamara Moyo, Jeanne Palmer, Yi Huang, et al. Abstract: S133 Session topic: 16. Myeloproliferative neoplasms – Clinical...
INTERIM ANALYSIS OF THE DALIAH TRIAL – A RANDOMIZED CONTROLLED PHASE III CLINICAL TRIAL COMPARING RECOMBINANT INTERFERON ALPHA-2 VS. HYDROXYUREA IN MPN PATIENTS
13 októbra, 2020 5:56 pm Leave your thoughtsAuthor(s): Trine Alma Knudsen, Dennis Lund Hansen, Lukas Frans Ocias, et al. Abstract: S131 Session topic: 16. Myeloproliferative...
23. KONGRES EURÓPSKEJ HEMATOLOGICKEJ ASOCIÁCIE: Myeloproliferatívna neoplázia
13 októbra, 2020 5:56 pm Leave your thoughtsKongres Európskej hematologickej asociácie s bohatým programom zahŕňajúcim viac ako 200 ústnych prezentácií a 1 300 posterov sa právom radí medzi najvýznamnejšie udalosti...
OPTIMISMM: PHASE 3 TRIAL OF POMALIDOMIDE, BORTEZOMIB, AND LOW–DOSE DEXAMETHASONE VS BORTEZOMIB AND LOW-DOSE DEXAMETHASONE IN LENALIDOMIDE-EXPOSED PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA
13 októbra, 2020 5:56 pm Leave your thoughtsAuthor(s): Paul Richardson, Albert Oriol Rocafiguera, Meral Beksac, et al. Abstract: S847 Session topic: 14. Myeloma and other...
ONCE-WEEKLY VS TWICE-WEEKLY CARFILZOMIB DOSING PLUS DEXAMETHASONE IN PATIENTS WITH RELAPSED AND REFRACTORY MULTIPLE MYELOMA (RRMM): RESULTS OF THE RANDOMIZED PHASE 3 STUDY A.R.R.O.W.
13 októbra, 2020 5:56 pm Leave your thoughtsAuthor(s): Maria-Victoria Mateos, Philippe Moreau, James R. Berenson, et al. Abstract: S849 Session topic: 14. Myeloma and other...
BUSULFAN + MELPHALAN WAS ASSOCIATED WITH A LONGER PFS COMPARED TO MELPHALAN ALONE IN HIGH-RISK MULTIPLE MYELOMA IN A RANDOMIZED PHASE 3 CLINICAL TRIAL
13 októbra, 2020 5:56 pm Leave your thoughtsAuthor(s): Muzaffar Qazilbash, Qaiser Bashir, Peter Thall, et al. Abstract: S124 Session topic: 23. Stem cell transplantation –...
LENALIDOMIDE-PREDNISONE VS LENALIDOMIDE ALONE MAINTENANCE IN NEWLY DIAGNOSED MULTIPLE MYELOMA: INDIVIDUAL PATIENT DATA META-ANALYSIS OF 2 RANDOMIZED PHASE III TRIALS
13 októbra, 2020 5:56 pm Leave your thoughtsAuthor(s): Francesca Gay, Lorenzo De Paoli, Alessandra Larocca Abstract: PS1299 Session topic: 14. Myeloma and other monoclonal gammopathies...
CONSOLIDATION FOLLOWED BY MAINTENANCE VS MAINTENANCE ALONE IN NEWLY DIAGNOSED, TRANSPLANT ELIGIBLE MULTIPLE MYELOMA: A RANDOMIZED PHASE 3 STUDY OF THE EUROPEAN MYELOMA NETWORK (EMN02/HO95 MM TRIAL)
13 októbra, 2020 5:56 pm Leave your thoughtsAuthor(s): P Sonneveld, M Beksac, B vanderHolt, et al. Abstract: S108 Session topic: 14. Myeloma and other monoclonal...
A TRIPLET BORTEZOMIB- AND IMMUNOMODULATOR-BASED THERAPY BEFORE AND AFTER DOUBLE ASCT IMPROVES OVERALL SURVIVAL OF NEWLY DIAGNOSED MM PATIENTS: FINAL ANALYSIS OF PHASE 3 GIMEMA-MMY-3006 STUDY
13 októbra, 2020 5:56 pm Leave your thoughtsAuthor(s): Paola Tacchetti, Francesca Patriarca, Maria Teresa Petrucci, et al. Abstract: S105 Session topic: 14. Myeloma and other...